Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

References

Page 1

	Year	Citations
Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) Scott M. Grundy JAMA Metabolic SyndromeHypertensionSecond ReportPrimary PreventionCardiovascular Disease	1993	27.9K
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Evaluation Expert Panel on Detection JAMA OtorhinolaryngologyHyperlipidemiaSurgeryMedical DiagnosisWebsite Uses Cookies	2001	25.8K
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents Annals of Internal Medicine	1998	5.2K
UPDATE ON DRUG RESISTANCE MUTATIONS IN HIV-1 &NA; Infectious Diseases in Clinical Practice ImmunodeficienciesGeneticsImmunologyAntiviral DrugDrug Resistance	2001	1.7K
Treatment for Adult HIV Infection Scott M. Hammer, Michael S. Saag, Mauro Schechter, JAMA	2006	1K
Treatment for Adult HIV Infection Patrick Yéni, Scott M. Hammer, Martin Hirsch, JAMA	2004	736
TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates Sandra De Meyer, Hilde Azijn, Dominique Surleraux, Antimicrobial Agents and Chemotherapy Broad RangeProtease InhibitorAntiviral ActivityMedicineHiv-1 Lai	2005	354
Incidence and Risk Factors for Immune Reconstitution Inflammatory Syndrome in an Ethnically Diverse HIV Type 1-Infected Cohort Irani Ratnam, Chen‐Yuan Chiu, N-B Kandala, Clinical Infectious Diseases	2006	349
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials Charles B. Hicks, Pedro Cahn, David A. Cooper, The Lancet Durable EfficacyTreatment-experienced Hiv-1-infected PatientsHiv/aids CounsellingStrategic InterventionHealth Sciences	2006	322
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures Margaret Johnson, Beatriz Grinsztejn, Claudia Rodríguez, AIDS	2005	249

Page 1